### 2.2.1	In vitro / physicochemical data

A literature search was carried out to collect available information on physicochemical properties of eryhtromycin. The obtained information from the literature is summarized in the table below and is used for model building.

| **Parameter**             | **Unit** | **Literature**                                               | **Description**                                              |
| :------------------------ | -------- | ------------------------------------------------------------ | ------------------------------------------------------------ |
| Molecular weight          | g/mol    | 308.765 ([drugbank.ca](# 5 References))                      | Molecular weight                                             |
| pK<sub>a</sub> (basic)    |          | 2.40 ([Cho 1983](# 5 References), [Raymond 1986](# 5 References)); 2.48 ± 0.01 ([Manchester 2018](# 5 References)) | Acid dissociation constant                                   |
| logP                      |          | 2.19 ([Machatha 2004](# 5 References)); 2.92 ([Capobianco 1994](# 5 References)) | Partition coefficient between octanol and water              |
| logD                      |          | 3.06 ([Greenblatt 1983](# 5 References))                     | Partition coefficient between octanol and water at physiological pH |
| f<sub>u</sub>             |          | 0.20 ([Eberts 1980](# 5 References)); 0.233 ± 0.028<sup>a</sup> ([Schmith 1991](# 5 References)); 0.270 ± 0.017<sup>a</sup> ([Scavone 1988](# 5 References)); 0.284 ± 0.017<sup>a</sup> ([Scavone 1988](# 5 References)); 0.290 ± 0.025<sup>a</sup> ([Juhl 1984](# 5 References)); 0.298 [0.259 - 0.316]<sup>b</sup> ([Abernethy 1983](# 5 References)); 0.311 ± 0.026<sup>a</sup> ([Ochs 1986](# 5 References)); 0.316<sup>c</sup> ([Moschitto 1983](# 5 References)) | Fraction unbound in human plasma of healthy adults           |
| Water solubility (pH 1.2) | mg/L     | 12 ([drugbank.ca](# 5 References))                           | Estimated solubility in water at pH 1.2                      |
| Water solubility (pH 7.0) | mg/L     | 40 ([drugbank.ca](# 5 References))                           | Estimated solubility in water at pH 7.0                      |
| Water solubility          | mg/L     | 73 ([Loftsson 2006](# 5 References))                         | Experimentally measured solubility in water at 22°C - 24°C   |

<sup>a</sup> mean ± SD

<sup>b</sup> mean [range]

<sup>c</sup> mean

### 2.2.2	Clinical data

A literature search was carried out to collect alprazolam PK data in healthy adults. 

The following publications were found and used for model building and evaluation:

| Publication                            | Study description                                            |
| :------------------------------------- | :----------------------------------------------------------- |
| [Adams 1984](# 5 References)           | IV administration of 0.25 mg and 4 mg                        |
| [Bertz 1997](# 5 References)           | IV administration of 2 mg (young subjects group)             |
| [Eberts 1980](# 5 References)          | PO administration of 2 mg <sup>14</sup>C-alprazolam (no plasma concentration-time profile was reported, but the dose fraction excreted unchanged in urine was quantified) |
| [Eller 1990](# 5 References)           | PO administration of 1 mg (Treatment C: IR tablet in fasted state) |
| [Fleishaker 1989](# 5 References)      | IV administration of 1 mg (Treatment A)                      |
| [Fleishaker 1994](# 5 References)      | PO administration of 1 mg four times daily at irregular time intervals for 4 days (Control phase) |
| [Friedman 1991](# 5 References)        | PO administration of 1 mg                                    |
| [Greenblatt 1988](# 5 References)      | PO administration of 1 mg                                    |
| [Greenblatt 1992](# 5 References)      | PO administration of 1 mg (Control phase)                    |
| [Greenblatt 1998](# 5 References)      | PO administration of 1 mg (Trial A)                          |
| [Greenblatt 2000](# 5 References)      | PO administration of 1 mg (Control group)                    |
| [Juhl 1984](# 5 References)            | PO administration of 1 mg (Healthy control group)            |
| [Kaplan 1998](# 5 References)          | PO administration of 1 mg (young subjects group)             |
| [Kirkwood 1991](# 5 References)        | PO administration of 1 mg                                    |
| [Kroboth 1988](# 5 References)         | IV administration of 0.5 mg, 1 mg followed by 72 µg over 8 h, and 2 mg |
| [Lin 1988](# 5 References)             | IV administration of 0.5 mg and PO administration of 0.5 mg  |
| [Schmider 1999](# 5 References)        | PO administration of 1 mg (Control phase)                    |
| [Schmith 1991](# 5 References)         | PO administration of 0.5 mg and 2 mg (normal subjects group) |
| [Smith 1984](# 5 References)           | IV administration of 1 mg and PO administration of 1 mg      |
| [Venkatakrishnan 2005](# 5 References) | IV administration of 1 mg                                    |
| [Wennerholm 2005](# 5 References)      | PO administration of 1 mg                                    |
| [Yasui 1996](# 5 References)           | PO administration of 0.8 mg (Control phase)                  |
| [Yasui 1998](# 5 References)           | PO administration of 0.8 mg (Control phase)                  |
| [Yasui 2000](# 5 References)           | PO administration of 0.8 mg (Control phase)                  |

